Simon J. Evenett and Matt Linley | 19 Apr 2021

The scaling up of COVID-19 vaccine production in the United States is impressive. Depending on the decisions taken by the Biden Administration in the weeks ahead, surpluses of vaccines could soon arise. This note presents estimates of the size of that surplus under different scenarios, each reflecting a distinct policy choice by the White House.